Opendata, web and dolomites

FERTISSIMO

Oxidative Stress as a biomarker for Embryo Selection in IVF Process

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FERTISSIMO project word cloud

Explore the words cloud of the FERTISSIMO project. It provides you a very rough idea of what is the project "FERTISSIMO" about.

fertility    abstract    reproductive    incubated    quantitative    approved    body    stratification    patented    gfi    trade    serono    solid    practitioner    market    rates    incidence    analyzer    care    innovation    supply    huge    strategy    ultimate    pregnancy    linked    embryos    roadmap    grant    preparing    culture    examination    solution    meet    births    enabled    units    generation    implantation    platform    embryo    clinical    diagnostics    2014    validation    business    prestigious    chain    chf    commercialization    merck    tcl    model    carmel    sound    successfully    competition    invasive    point    thermochemiluminescence    deploying    route    biomarker    plan    proprietary    multiple    sme    2009    physicians    magazines    published    proof    patients    eureka    june    economical    profile    ivf    completion    series    stable    oxidative    thrilled    levels    fluids    risk    launch    probability    won    media    fertissimo    stress    biomarkers    reducing    ip   

Project "FERTISSIMO" data sheet

The following table provides information about the project.

Coordinator
CARMEL DIAGNOSTICS LTD 

Organization address
address: 9 BARLEV HAIM STREET
city: QIRYAT TIVON
postcode: 3608267
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www.carmel-diagnostics.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-03-01   to  2016-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CARMEL DIAGNOSTICS LTD IL (QIRYAT TIVON) coordinator 50˙000.00

Map

 Project objective

Abstract: Carmel Diagnostics, established in 2009, is an SME that has developed clinical applications of its novel, proprietary, patented Thermochemiluminescence technology platform – TCL Analyzer™. Carmel has successfully completed “proof of concept” for its main applications: Embryo Selection in IVF process and Risk Stratification for CHF patients. The results were published in leading magazines. The technology enables assessment of Oxidative Stress in body fluids using it as a biomarker for clinical problems linked to levels of oxidative stress. TCL Analyzer is a stable, robust Point of Care system, now in its third generation. There is a huge need, clinical and economical, for novel biomarkers that will enable the physicians with effective embryo selection. With the goal of identifying embryos of high implantation probability, Carmel’s non-invasive solution will meet this need by providing a quantitative assessment of an embryo’s reproductive potential based on a biomarker - the oxidative profile of the culture media in which the embryo is incubated. This will allow the practitioner to improve pregnancy rates while reducing the incidence of multiple births. The Phase-1 project will be focused on preparing sound business plan, based on solid business model and commercialization strategy and to plan the activities for deploying the solution. This will include market and competition analysis, IP analysis, supply chain examination, risk assessment, and preparing roadmap for the clinical validation, product completion and the best route to bring the system to the market and launch it successfully. In June, 2014 Carmel won a prestigious grant of GFI - Grant for Fertility Innovation (by Merck Serono) that enabled it to build a series of improved, stable TCL Analyzer units to be used in the clinical studies. Eureka approved the project as well. Carmel’s experienced management is thrilled to build FERTISSIMO, the ultimate Embryo selection system based on TCL Analyzer.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FERTISSIMO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FERTISSIMO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More